Trials, approvals, deal flow, and the long road from preclinical to pharmacy.
Clinical pipelines, drug approvals, and biotech deals.
AI-verified biotech and pharmaceutical intelligence with full provenance.
The biotech is seeking approval for a viral immunotherapy that previously faced two rejections, buoyed by productive talks under a new FDA commissioner.
Pfizer and Chinese biotech Innovent will jointly develop 12 early-stage antibodies and ADCs for various cancers in a pact worth up to $10.5 billion.
French pharma Servier is buying an experimental tablet for muscular dystrophy from Edgewise Therapeutics, with a deal valued at up to $2.7 billion including milestones.
The collaboration will focus on developing next-generation AAV gene therapy candidates for an unspecified muscle disease and in vivo cell therapy.
The funding aims to accelerate development of a vaccine targeting the Bundibugyo strain amid a worsening Ebola outbreak.
Researchers find coordinated neural patterns in zebrafish brains seconds before social behavior begins, with the pallium region playing a key role.
New research finds that created grassland habitats can effectively compensate for nature lost to development, helping bees and hoverflies.
A European research team is developing bacteria that convert sustainable methanol into chemical base materials, aiming to replace fossil resources in everyday products.
HKUMed researchers develop RNA Segment Editing (RSE), a novel tool that precisely removes or replaces faulty RNA segments in living cells.
A coalition of over 100 researchers from six Asian countries has unveiled a coordinated plan to create artificial single-celled biological systems from non-living molecules.
Researchers have mapped eight distinct metabolic niches that reveal how trillions of ocean microbes process carbon, offering new insights into the climate-regulating marine carbon cycle.
The field of targeted protein degradation is evolving with new tools for target validation and translational predictions.
A global coalition is accelerating development of three vaccines against the Ebola strain spreading in Congo, backed by $62 million in new funding.
A new programmable blood test allows scientists to monitor gene activity in the living brain without surgery.
A new neural probe combines electrophysiology and optogenetics to simultaneously record and control brain activity, offering a powerful tool for studying neural circuits.
KAIST researchers develop a sustainable method to produce key nylon building blocks using microorganisms.
Mid-cap buyers, a better capital raising climate, and manufacturing reshoring are shaping U.S. biopharma cluster growth, according to Genetic Engineering News.
Researchers have developed an affordable method to produce large quantities of uniform hydrogel capsules for 3D cell culture, democratizing access to advanced tissue-mimetic studies.
First-patient dosing in Crystalys Therapeutics' AMETHYST trial for dotinurad follows competitor Sobi's positive Phase III results for pozdeutinurad.
At the year's largest cancer conference, head-to-head data between bispecific antibodies and antibody-drug conjugates took center stage, alongside advances in targeting the challenging RAS pathway.
Rare disease company RallyBio announces a plan to merge with Avenzo Therapeutics after its prior deal with Candid Therapeutics fell through.
Using duckweed as an alternative to mammalian expression systems can help manufacturers navigate the patent cliff and shift from blockbusters to biosimilars.
A novel screening approach enables large-scale identification of membrane-permeable synthetic cyclic peptides, advancing a drug modality that blends biologic properties with oral bioavailability.
Industry experts argue artificial intelligence can accelerate clinical trials but cannot fix fundamental flaws in trial design or replace human oversight.
Researchers are preparing to test an oral antiviral for Ebola prevention in exposed individuals, a potential game-changer in outbreak control.
An industry expert argues that recombinant technologies offer a more reliable path for diagnostic test availability, citing concerns over traditional source dependence.
A shift in drug development combines in vivo models with novel methodologies to improve clinical relevance.
Macrocycles, de novo antibodies, and mRNA-based approaches are expanding the drug discovery toolkit for previously intractable targets.
Italian researchers led by Luigi Naldini have developed a new platform to make gene editing in hematopoietic stem cells more precise and safer.
Next-generation mass spectrometry and multiomics workflows accelerate biomarker discovery and therapeutic design.
Detailed study data confirms overall survival improvement for pancreatic cancer patients, marking a significant advance at ASCO.
Corning is helping researchers standardize, scale, and automate organoid science as FDA support for non-animal methods accelerates.
A new opinion piece and podcast discussion highlight the ethical and practical challenges for hospitals when patients demand blood from unvaccinated donors.
A compound originally dubbed 'substance God help me' by its creator finds renewed interest as federal health policy shifts.
Advances in throughput have shifted the critical challenge in spatial atlasing to achieving sufficient sensitivity to detect low-abundance cell populations.
Researchers used AI to analyze CT scans and discovered that a healthier thymus, an often-overlooked organ, correlates with longer life and reduced risks of heart disease and cancer.
New research highlights the use of human brain organoids to evaluate anti-inflammatory therapies for CNS disorders, addressing a gap in clinical success.
A new report highlights the commercial durability and strategic relevance of orphan drugs, supported by a strong development pipeline for 2026.
Agilent shares jumped 17% on Thursday, their best single-day performance since 2002, after the life sciences tools company reported stronger-than-anticipated fiscal second-quarter results.
Researchers propose biodegradable hydrogel coatings made from natural polymers to improve seed germination and reduce environmental impact.
A new study reveals deer keds shed their wings and lose their vision after latching onto a host, adapting to a life of parasitism.
Crystal structures reveal a distinct mechanism bacteria employ to import β-1,2-glucans, rare sugar polymers with complex biological roles.
Melanoma metastasis risk peaks in middle age and declines in very old age, driven by a specific immune cell that keeps cancer dormant.
New research reveals how mechanical stress and cell shape steer stomata development, offering insights into plant growth dynamics.
New research reveals that mosquitoes can overcome DEET's repellent effect by learning to link the scent with a food source.
A clinical trial suggests that ultra-low doses of nivolumab may extend survival in head and neck cancer, offering a path to affordable treatment in low-resource settings.
Scientists identified a chemically altered protein, STING, that keeps the brain’s immune system in overdrive, damaging neural connections in Alzheimer’s disease.
Scientists discover that iron-filled immune cells in pigeons' livers may serve as magnetic sensors, solving a decades-old puzzle about animal navigation.
University of Tennessee researchers identify a hidden protein in tick saliva that could lead to new methods to prevent transmission of viruses and bacteria.
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
A new study finds that intermittent fasting alters brain activity and gut bacteria in obese adults, suggesting a coordinated gut-brain mechanism behind weight loss.
A new Nature study reports that personalized immune cells may halt or reverse liver damage caused by cirrhosis.
A new study published in Nature uncovers the mechanism by which common bacteria attach protective protein layers.
A new study suggests omega-3 fish oil may help improve blood sugar control and reduce insulin resistance, offering potential benefits for type 2 diabetes management.
In a medical milestone, surgeons transplant genetically modified pig liver and kidneys into a human recipient, raising hopes for alleviating organ shortages.
Scientific sleuths have identified more than 100 potentially manipulated or duplicated images in the antibody catalogue of life sciences giant Thermo Fisher Scientific.
At the ASCO conference, BioNTech and Pfizer released promising data on bispecific antibodies for lung cancer, while FDA's Rick Pazdur offered his perspective.
A new nanofiber implant developed by University of Cincinnati and Johns Hopkins researchers delivers three drugs directly to brain tumors, doubling survival in mouse studies.
A new study documents the first possible case of a cat transmitting bird flu to a human, while another reveals genetic tumor similarities between cats and humans.
Scientists developed eye drops with spinach-derived photosynthetic machinery that restored moisture in mouse eyes, offering a novel approach to dry eye treatment.
FDA official Rick Pazdur says the agency's current challenges present an opportunity for rebuilding, not just restoration.
This week's science highlights reveal a climate tipping point in the Arctic, sustainability concerns for scuba tourism on coral reefs, and promising results from an experimental mRNA Ebola vaccine.
Non-native wall lizards in Cincinnati overcame inbreeding through rapid population expansion, according to new genomic research.
New research shows that caffeine can restore social memory by repairing a specific brain circuit damaged by lack of sleep.
A four-week clinical trial shows a specially formulated tomato-soy juice significantly lowered inflammatory proteins in adults with obesity.
New research links the gut microbiome of the Gulf toadfish to the formation of carbon-trapping minerals, highlighting a novel marine carbon cycle pathway.
The startup, which helps oncologists automate data-intensive tasks, secured $22M in Series B funding following a $15M Series A in 2024.
The sequencing giant introduces a whole-genome-based MRD kit for cancer monitoring on NovaSeq X systems, aiming to broaden clinical research adoption.
Researchers created a spatial atlas showing how these immune structures vary between tumor types and may impact patient outcomes.
David Chang is stepping down as CEO of Allogene Therapeutics, the company announced, marking a leadership change for the cell therapy biotech.
A new method reveals region-specific routes for brain waste removal, showing how inflammation and Alzheimer's disrupt clearance pathways.
The collaboration will combine closed-loop functional screening with AI-driven design to discover delivery systems for oligotherapeutics targeting previously inaccessible tissues.
A physician raises concerns about the growing trend of using tiny doses of GLP-1 drugs for cosmetic weight loss despite a lack of evidence on long-term effects.
Researchers have developed a gene-based clock that can predict a person's time to death and assess their biological age, according to a Nature News report.
A commentary in The Lancet highlights the complexities and mixed results of trials testing prasinezumab, an antibody targeting α-synuclein, to slow Parkinson's progression.
Two phase 3b trials published in The Lancet show ocrelizumab delays disability progression in primary progressive MS across a wider patient group, but a higher dose did not enhance efficacy in relapsing or progressive forms.
Eli Lilly's triple hormone receptor agonist retatrutide shows a mean 28.3% weight reduction in Phase 3 trials over 80 weeks, exceeding approved GLP-1 drugs but with a higher severity of gastrointestinal side effects.
A SpaceNews analysis argues that establishing a permanent human presence on the Moon requires increased investment in biological research to support life in harsh lunar conditions.
Longtime industry executive Jeremy Levin warns that American supremacy in biotech is threatened by weaknesses in regulatory and investment structures.
Multi-institutional study identifies a metabolic mechanism that weakens DNA repair in resistant ovarian cancer cells, potentially restoring chemotherapy effectiveness.
New trial results for bepirovirsen suggest a potential breakthrough in treating chronic hepatitis B, with physicians calling the findings a 'historic moment'.
CVS Caremark's new agreement includes Lilly's oral drug Foundayo and restores Zepbound coverage, removing Novo Nordisk's commercial advantage.
Strong clinical data on pancreatic cancer therapies are expected to dominate discussions at the American Society of Clinical Oncology annual meeting in Chicago.
Investors are turning to biotech stocks as the world continues to recover from the global pandemic, with hopes pinned on ongoing vaccine and booster development.
An experimental GSK drug helped 1 in 5 patients with chronic hepatitis B achieve a functional cure, showing significantly better results than current treatments.
Researchers unveil PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing, with a compact version showing therapeutic promise in mouse models.
A new study in Nature reveals common gene expression changes across mammalian species that correlate with ageing and mortality.
Correspondence in The Lancet challenges the SCIENCE trial's choice of a general upper-limb function measure over an elbow-specific tool for pediatric medial epicondyle fractures.
A large-scale biobank analysis has identified more than 88,000 genetic associations with metabolic traits, offering new insights into disease mechanisms.
A new biologic targeting the ST2/IL-33 pathway lowered annual exacerbation rates in patients with frequent COPD exacerbations, though a confirmatory phase 3 trial missed statistical significance.
Biotech M&A surges 81% to $240B in 2025 as industry pivots toward novel immunotherapy targets ahead of ASCO 2026.
New research reveals that hematopoietic stem cells can remember previous inflammatory stress, potentially altering future immune responses.
Amputated sea cucumber tissue remains viable for years, exhibiting cell diversification and immune activity, challenging definitions of life.
Founders, investors, and biohackers gathered to debate strategies for extending human life, signaling the topic's transition from niche interest to mainstream industry.
Eli Lilly's high-dose gene-editing therapy reduced LDL cholesterol by 62% in a Phase 1 study, marking a potential breakthrough in cardiovascular genetic medicine.
Eli Lilly plans to acquire Vaccine Company, Curevo, and LimmaTech Biologics in a deal worth up to $3.8 billion, targeting viral and bacterial pathogens linked to long-term health risks.
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. for nearly $4 billion to build an infectious disease portfolio.
A new multimodal imaging dataset, MOSAIC, is designed to train AI models to analyze living biological systems with unprecedented detail.